Cereno Scientific AB Class B

As of June 30, 2026, Cereno Scientific AB Class B carries a market capitalization of 1.65B, placing it among publicly traded companies globally. Its enterprise value stands at 1.79B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Cereno Scientific AB Class B's next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Cereno Scientific AB Class B has 312.09M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Cereno Scientific AB Class B maintains a current ratio of 0.51, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 88.21, indicating elevated leverage, while an interest coverage ratio of -1.79 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Cereno Scientific AB Class B posted a negative return on equity (ROE) of -68.81, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -29.76, reflecting losses generated across the asset base.

As of the close on October 23, 2026, Cereno Scientific AB Class B's stock has declined approximately 61.04% over the past 52 weeks. The 50-day moving average sits at 4.15, while the 200-day moving average is 5.38.

Over the twelve months ended June 30, 2026, Cereno Scientific AB Class B generated - - in revenue and converted that into -125.16M in net income, yielding earnings per share of -0.38. EBITDA reached -80.76M, while operating income came in at -81.55M.

As of June 30, 2026, Cereno Scientific AB Class B holds 38.98M in cash and equivalents against 175.00M in total debt, resulting in a net debt position of 136.02M. Total book value stands at 198.40M, with working capital of -41.89M providing operational flexibility.

Cereno Scientific AB Class B produced -52.79M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -113.49M in capital expenditures, free cash flow totaled -166.28M - equivalent to -0.55 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -9.58: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -8.86, meaning Cereno Scientific AB Class B raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Cereno Scientific AB Class B's most recent stock split took place on May 20, 2019 with a 151:157 split ratio.